The National Institute for Health and Clinical Excellence (NICE) has published new guidance to approve the use of Liraglutide (also known as Victoza) for people with Type 2 diabetes across England, Wales and Northern Ireland.As a result, NICE is instructing Primary Care Trusts across the NHS to find compulsory funding for Liraglutide within three months to ensure it is available for all people with Type 2 diabetes that meet the NICE recommendations.
Liraglutide is a once daily injectable treatment that acts to help people with Type 2 diabetes achieve good glycaemic control by stimulating the release of insulin when glucose levels get too high and also reduces appetite.
NICE has now approved Liraglutide 1.2mg once-daily as a valuable treatment option for people with Type 2 diabetes as a dual or triple therapy with an oral treatment.
NICE guidance stipulates that treatments should only be continued if blood glucose levels reduce within six months and those undergoing triple therapy manage to lose three per cent of their initial body weight.
Increasing choices for people with Type 2 diabetes
“We welcome the fact that NICE guidance will help to standardise availability of Liraglutide (Victoza) on the NHS as it means another treatment option is available to support people with Type 2 diabetes to manage their condition,” said Stella Valerkou, Diabetes UK Senior Policy Officer. “We also welcome the recommendations that mean Liraglutide could be available earlier in the treatment process, increasing the choices for people with Type 2 diabetes.
“Diabetes UK advocates that lifestyle changes should be the first step in helping with weight management but recognise that this treatment option has shown additional benefits in terms of weight loss as well as blood glucose control and that this can be an important consideration for some people with Type 2 diabetes."However Diabetes UK believes decisions about when to stop or change treatments should always be agreed between individuals and their healthcare professional, based on personal needs and not pre-determined, and that the potential risks and benefits of treatment options should be discussed to support people to reach an informed decision.”View the NICE guidance on Liraglutide.